Nov.11, 2022 | Tumor centric- and liquid biomarkers for guiding treatment decisions in bladder cancer - Lars Dyrskjøt Andersen, PhD

Sept 12th, 2022 - Adoptive immunotherapy with tumor-infiltrating T lymphocytes: developing new cell products and initiating a clinical program for solid cancer patients - Simon Turcotte, MD, MSc, FRCSC

June 6th, 2022 | Clinical utility & impact of targeted nucleic acid sequencing in myeloid malignancies and precursor lesions - Christina Ferrone, PhD

April 4th, 2022 | Pragmatic Clinical Trials – Living the evolution of a concept - Joseph L. Pater, MD, MSc, FRCP(C)

March 7, 2022 | The RNA epigenetics-m6A epitranscriptomic regulation in cancer - Hansen He, PhD

Feb 7, 2022 | Where are we up to with biomarkers in cancer immunotherapy? - Andrew Miles, PhD

Jan 10, 2022 | - Personal Reflections on Over 35 Years of Cancer Research - Elizabeth Eisenhauer, OC MD FRCPC FRSC

Nov 1, 2021 | STAT1-induced inflammation potentiates oxidative stress to increase the therapeutic impact of complex I inhibitors in breast cancer - Josie Ursini-Siegel, PhD

Oct 4, 2021 | Women, power, and the cancer divide - Ophira Ginsburg, MSc, MD

Sept 7, 2021 | Development & application of a molecular classification system for urothelial cancer - Gottfrid Sjödahl, PhD

July 19, 2021 | Biomarker Development in Colorectal Cancer – Preparation Today for Future Success - Jonathan Loree, MD, MSc, FRCPC

June 7, 2021 | From the Clinic to the Lab: Investigating Mechanisms of Response and Resistance to Immune Checkpoint Therapy - Padmanee Sharma, MD, PhD

May 3, 2021 | Dissecting Mucosal Immunity in the Bladder - Molly Ingersoll, PhD

April 12, 2021 | Interventional Pharmacoeconomics and anything else of interest - Daniel Goldstein, MD

March 1, 2021 | Novel insights into recalcitrant subtypes of lung cancer - Triparna Sen, PhD